LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.